The investigators want to have a collection of fresh primary or recurrent tumor tissue for establishment of patients-derived xenografts in order to:
generate a biobank of in vivo patient xenografts representing the different subgroups of tumors for head and neck cancer
* perform genetic and transcriptional profiling of the primary, metastatic tumors and xenograft tumors * evaluate the efficacy of new targeted agents, whether or not in combination with standard treatment options * evaluate biomarkers of drug sensitivity * study primary and secondary (acquired) resistance in these models
In the first phase, all patients with primary or recurrent/ metastatic disease of head and neck cancer can be included pre-operatively or before a tumor biopsy after obtaining informed consent
Data on stage, grade, histology, adjuvant treatment, responses, relapse should be available
Follow-up data should be available
Patients with recurrent disease are allowed
None
All patients with a primary advanced or recurrent head and neck tumor. * Inclusion preoperatively or before biopsy * Written informed consent prior to surgery or biopsy
Cohort
Prospective
Local biopsy in the tumor
Procedure/SurgeryA tumor biopsy of 0.5 cm2 or more will be collected from every patient during surgery or endoscopy after informed consent and if there is enough material after review by the pathologist.
Identification of the biomarkers of new cancer therapies for head and neck cancer on the patient-derived xenografts with immunohistochemistry (KI67) on FFPE (fixation followed by paraffin embedding) slides
Identification of the biomarkers of new cancer therapies for head and neck
Characterization of the biomarkers of new cancer therapies for head and neck cancer on the patient-derived xenografts with genetic techniques
Characterization of the biomarkers of new cancer therapies for head and neck cancer on the patient-derived xenografts with genetic techniques
Click on the lead sponsor to view all of their trials.
